Robert W Hegarty
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Robert W Hegarty has a total of 3 co-authors. Here are the top co-authors by number of shared publications:
- Joel N. Blankson
Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, MD, USA
1 shared publication - Karen A O'Connell
Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, Maryland 21287, USA
1 shared publication - Robert F. Siliciano
Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, MD, USA
1 shared publication
Latest Publications
- Open Access
- 3 August 2011
- Published by Springer Nature in Retrovirology
- Vol. 8 (1) , 63
Viral suppression of multiple escape mutants by de novo CD8+T cell responses in a human immunodeficiency virus-1 Infected elite suppressor
Elite suppressors or controllers (ES) are HIV-1 infected patients who maintain undetectable viral loads without treatment. While HLA-B*57-positive ES are usually infected with virus that is unmutated at CTL epitopes, a single, dominant variant containing CTL escape mutations is typically seen in plasma during chronic infection. We describe an ES who developed seven distinct and rare escape variants at an HLA-B*57-restricted Gag epitope over a five year period. Interestingly, he developed proliferative, de novo CTL responses that suppressed replication of each of these variants. These responses, in combination with low viral fitness of each variant, may contribute to sustained elite control in this ES.
- 3 August 2011
- Published by Springer Nature in Retrovirology
- Vol. 8 (1) , 63
Open AccessViral suppression of multiple escape mutants by de novo CD8+T cell responses in a human immunodeficiency virus-1 Infected elite suppressor
Elite suppressors or controllers (ES) are HIV-1 infected patients who maintain undetectable viral loads without treatment. While HLA-B*57-positive ES are usually infected with virus that is unmutated at CTL epitopes, a single, dominant variant containing CTL escape mutations is typically seen in plasma during chronic infection. We describe an ES who developed seven distinct and rare escape variants at an HLA-B*57-restricted Gag epitope over a five year period. Interestingly, he developed proliferative, de novo CTL responses that suppressed replication of each of these variants. These responses, in combination with low viral fitness of each variant, may contribute to sustained elite control in this ES.